ReviewEuropean heart journal2023

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.

Eugene Braunwald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.